ONS ONCC Chemo Renewal II Questions
and answers
Key Points for Combination Therapy - ANSWER-Oncology Nurses must consider
Consider the potential toxicity related to each drug.
Understand the monitoring guidelines for each drug.
Have knowledge of clinically significant signs and symptoms
ONS Evidence-Based Practice Resources - ANSWER-Evidence-based practice
can have positive effects, such as:
Improved patient outcomes
Increased nurse satisfaction
Potential cost savings
Risk Factors For Colon Cancer - ANSWER-Increased age is a risk factor for
developing colorectal cancer. The chance of developing colorectal cancer
increases markedly after age 50. Roughly 9 out of 10 people diagnosed with
colorectal cancer are at least 50 years old. Smoking, alcohol intake, and a
personal history of polyps are all things that increase risk. Other risk factors for
the development of colorectal cancer include:
Racial and ethnic backgrounds (African Americans and Jews of Eastern
European descent [Ashkenazi Jews] have highest incidence)
Diet high in red and processed meats
Physical inactivity, obesity
Type 2 diabetes
Family history of colon cancer or inflammatory bowel disease
Inherited familial syndromes (FAP, HNPCC)
Patient Education on Chemotherapy - ANSWER-Patients are provided with
verbal and written or electronic information as part of an education process
,before the first administration of treatment of each treatment plan. The content of
this educational material will be documented. Educational information includes
the following at a minimum:
Patient's diagnosis
Goals of treatment; that is, cure disease, prolong life, or reduce symptoms
Planned duration of treatment, schedule of treatment administration, drug names
and supportive medications, drug-drug and drug-food interactions, and plan for
missed doses
Potential long-term and short-term adverse effects of therapy, including infertility
risks for appropriate patients
Symptoms or adverse effects that require the patient to contact the healthcare
setting or to seek immediate attention
Symptoms or events that require immediate discontinuation of oral or other
self-administered treatments
Procedures for handling medications in the home, including storage, safe
handling, and management of unused medication
Procedures for handling body secretions and waste in the home
Follow-up plans, including laboratory and provider visits
Contact information for the healthcare setting, with availability and instructions on
when and who to call
The missed appointment policy of the healthcare setting and expectations for
rescheduling or cancelling
Education includes family, caregivers, or others based on the patient's ability to
assume responsibility for managing therapy. Educational activities will be
performed based on the patient's learning needs, abilities, preferences, and
readiness to learn.
Folfox 6 - ANSWER-he treatment regimen, FOLFOX6, consists of chemotherapy
in two-week cycles over a six-month period. Ensuring patient understanding of
the treatment and anticipated side effects before initiation of therapy is an
important safety standard and should be documented in the patient record
(Neuss et al., 2016). Mr. Patterson is also provided written information regarding
his chemotherapy regimen to review at home. Mr. Patterson's treatment plan with
FOLFOX6 consists of the following:
Oxaliplatin 100 mg/m2 and Leucovorin 400 mg/m2 IV over two hours, then
,5-fluorouracil (5-FU) 400 mg/m2 IV bolus, followed by
5-FU 3,000 mg/m2 IV by continuous infusion over 46 hours
You have a long discussion with Mr. Patterson about his chemotherapy regimen,
including his need for a port placement for IV access since he will be receiving
5-FU by continuous infusion for 46 hours. You discuss each agent in detail with
Mr. Patterson, including the potential side effects of the agents he will receive.
Your teaching highlights self-management strategies for these toxicities as well
as when and how to reach someone from the office at any time of day.
Which of the following is a unique side effect that occurs with the agent
oxaliplatin? - ANSWER-. Cold sensory neuropathy
Cold Sensory Neuropathy - ANSWER-Per the prescribing information for
oxaliplatin, "the cold sensory neuropathy is an acute, reversible, primarily
peripheral, sensory neuropathy of early onset (occurring within hours or one to
two days of dosing) which resolves within 14 days, but frequently recurs with
further dosing." The symptoms may be precipitated or exacerbated by exposure
to cold temperature or cold objects. They usually present as transient
paresthesia, dysesthesia, and hypoesthesia in the hands, feet, perioral area, or
throat. Jaw spasm, abnormal tongue sensation, dysarthria, eye pain, and a
feeling of chest pressure have also been observed. Exposure to cold can cause
very painful sensations following oxaliplatin therapy. Mr. Patterson is encouraged
to avoid cold temperatures during the days following chemotherapy. Resolution of
this side effect usually occurs within five days following therapy, but may last
longer (Sanofi-Aventis, 2014).
peripheral neuropathy - ANSWER-disorder of the peripheral nerves that carry
information to and from the brain and spinal cord
folfox 6 side effects - ANSWER-You discuss many other side effects of the
agents (oxaliplatin, leucovorin, and 5-FU) that Mr. Patterson will receive. You
cover the following common side effects of this chemotherapy regimen:
peripheral neuropathy, myelosuppression, N/V/D, fatigue, fever, mucositis,
alopecia, anorexia, and photosensitivity. You provide Mr. Patterson written
handouts that review this same information.
, ONS PEP resources include evidence-based information on some of these side
effects:
Peripheral Neuropathy
Prevention of Infection
CINV
Diarrhea
Fatigue
Mucositis
Anorexia
Which of the following are recommended as standard PPE when there is any
potential exposure for hazardous drugs? (select all that apply) - ANSWER-. Face
shield
. Two pairs chemotherapy tested gloves
Single use gown with back closure
PPE should be worn whenever there is a potential that hazardous drugs could be
released into the environment, such as in the following situations: -
ANSWER-Administering HDs by any route (PO, IV, IT, etc.)
Handling any HD vials, ampules, or packaging materials
Introducing or withdrawing needles or dispensing pins from HD vials
Transferring drugs from HD vials to other containers using needles, dispensing
pins, or syringes
Opening ampules or HDs
Expelling air from an HD-filled syringe
Spiking IV bags containing HDs and changing IV tubing
Priming IV tubing with HDs
Handling HD leakage from tubing, syringe, and connection sites
Discontinuing infusions of HDs
Disposing of HDs and items contaminated by HDs
Handling the body fluids of a patient who had received HDs in the past 48 hours
Cleaning HD spills
Touching any surface that is potentially contaminated with HD residue
Colorectal Cancer Incidence Increasing in Young Adults - ANSWER-Colorectal
cancer (CRC) incidence rates have been declining in the United States for
and answers
Key Points for Combination Therapy - ANSWER-Oncology Nurses must consider
Consider the potential toxicity related to each drug.
Understand the monitoring guidelines for each drug.
Have knowledge of clinically significant signs and symptoms
ONS Evidence-Based Practice Resources - ANSWER-Evidence-based practice
can have positive effects, such as:
Improved patient outcomes
Increased nurse satisfaction
Potential cost savings
Risk Factors For Colon Cancer - ANSWER-Increased age is a risk factor for
developing colorectal cancer. The chance of developing colorectal cancer
increases markedly after age 50. Roughly 9 out of 10 people diagnosed with
colorectal cancer are at least 50 years old. Smoking, alcohol intake, and a
personal history of polyps are all things that increase risk. Other risk factors for
the development of colorectal cancer include:
Racial and ethnic backgrounds (African Americans and Jews of Eastern
European descent [Ashkenazi Jews] have highest incidence)
Diet high in red and processed meats
Physical inactivity, obesity
Type 2 diabetes
Family history of colon cancer or inflammatory bowel disease
Inherited familial syndromes (FAP, HNPCC)
Patient Education on Chemotherapy - ANSWER-Patients are provided with
verbal and written or electronic information as part of an education process
,before the first administration of treatment of each treatment plan. The content of
this educational material will be documented. Educational information includes
the following at a minimum:
Patient's diagnosis
Goals of treatment; that is, cure disease, prolong life, or reduce symptoms
Planned duration of treatment, schedule of treatment administration, drug names
and supportive medications, drug-drug and drug-food interactions, and plan for
missed doses
Potential long-term and short-term adverse effects of therapy, including infertility
risks for appropriate patients
Symptoms or adverse effects that require the patient to contact the healthcare
setting or to seek immediate attention
Symptoms or events that require immediate discontinuation of oral or other
self-administered treatments
Procedures for handling medications in the home, including storage, safe
handling, and management of unused medication
Procedures for handling body secretions and waste in the home
Follow-up plans, including laboratory and provider visits
Contact information for the healthcare setting, with availability and instructions on
when and who to call
The missed appointment policy of the healthcare setting and expectations for
rescheduling or cancelling
Education includes family, caregivers, or others based on the patient's ability to
assume responsibility for managing therapy. Educational activities will be
performed based on the patient's learning needs, abilities, preferences, and
readiness to learn.
Folfox 6 - ANSWER-he treatment regimen, FOLFOX6, consists of chemotherapy
in two-week cycles over a six-month period. Ensuring patient understanding of
the treatment and anticipated side effects before initiation of therapy is an
important safety standard and should be documented in the patient record
(Neuss et al., 2016). Mr. Patterson is also provided written information regarding
his chemotherapy regimen to review at home. Mr. Patterson's treatment plan with
FOLFOX6 consists of the following:
Oxaliplatin 100 mg/m2 and Leucovorin 400 mg/m2 IV over two hours, then
,5-fluorouracil (5-FU) 400 mg/m2 IV bolus, followed by
5-FU 3,000 mg/m2 IV by continuous infusion over 46 hours
You have a long discussion with Mr. Patterson about his chemotherapy regimen,
including his need for a port placement for IV access since he will be receiving
5-FU by continuous infusion for 46 hours. You discuss each agent in detail with
Mr. Patterson, including the potential side effects of the agents he will receive.
Your teaching highlights self-management strategies for these toxicities as well
as when and how to reach someone from the office at any time of day.
Which of the following is a unique side effect that occurs with the agent
oxaliplatin? - ANSWER-. Cold sensory neuropathy
Cold Sensory Neuropathy - ANSWER-Per the prescribing information for
oxaliplatin, "the cold sensory neuropathy is an acute, reversible, primarily
peripheral, sensory neuropathy of early onset (occurring within hours or one to
two days of dosing) which resolves within 14 days, but frequently recurs with
further dosing." The symptoms may be precipitated or exacerbated by exposure
to cold temperature or cold objects. They usually present as transient
paresthesia, dysesthesia, and hypoesthesia in the hands, feet, perioral area, or
throat. Jaw spasm, abnormal tongue sensation, dysarthria, eye pain, and a
feeling of chest pressure have also been observed. Exposure to cold can cause
very painful sensations following oxaliplatin therapy. Mr. Patterson is encouraged
to avoid cold temperatures during the days following chemotherapy. Resolution of
this side effect usually occurs within five days following therapy, but may last
longer (Sanofi-Aventis, 2014).
peripheral neuropathy - ANSWER-disorder of the peripheral nerves that carry
information to and from the brain and spinal cord
folfox 6 side effects - ANSWER-You discuss many other side effects of the
agents (oxaliplatin, leucovorin, and 5-FU) that Mr. Patterson will receive. You
cover the following common side effects of this chemotherapy regimen:
peripheral neuropathy, myelosuppression, N/V/D, fatigue, fever, mucositis,
alopecia, anorexia, and photosensitivity. You provide Mr. Patterson written
handouts that review this same information.
, ONS PEP resources include evidence-based information on some of these side
effects:
Peripheral Neuropathy
Prevention of Infection
CINV
Diarrhea
Fatigue
Mucositis
Anorexia
Which of the following are recommended as standard PPE when there is any
potential exposure for hazardous drugs? (select all that apply) - ANSWER-. Face
shield
. Two pairs chemotherapy tested gloves
Single use gown with back closure
PPE should be worn whenever there is a potential that hazardous drugs could be
released into the environment, such as in the following situations: -
ANSWER-Administering HDs by any route (PO, IV, IT, etc.)
Handling any HD vials, ampules, or packaging materials
Introducing or withdrawing needles or dispensing pins from HD vials
Transferring drugs from HD vials to other containers using needles, dispensing
pins, or syringes
Opening ampules or HDs
Expelling air from an HD-filled syringe
Spiking IV bags containing HDs and changing IV tubing
Priming IV tubing with HDs
Handling HD leakage from tubing, syringe, and connection sites
Discontinuing infusions of HDs
Disposing of HDs and items contaminated by HDs
Handling the body fluids of a patient who had received HDs in the past 48 hours
Cleaning HD spills
Touching any surface that is potentially contaminated with HD residue
Colorectal Cancer Incidence Increasing in Young Adults - ANSWER-Colorectal
cancer (CRC) incidence rates have been declining in the United States for
